Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

AstraZeneca : As coronavirus soars, U.S. cheers Britain's vaccine approval

12/02/2020 | 02:34pm EST

NEW YORK, Dec 2 (Reuters) - U.S. health experts on Wednesday welcomed British emergency approval of Pfizer Inc's COVID-19 vaccine, a sign that U.S. regulators may soon follow suit in a bid to bring the surging pandemic under control.

As U.S. coronavirus hospitalizations jumped to their highest since the onset of the global pandemic, Britain gave emergency use approval to the vaccine developed by Pfizer and German partner BioNTech SE, the first country to do so.

Britain said it would start inoculating high-risk people early next week, a move that could make Americans more confident about the prospect of an expected mass vaccination campaign reminiscent of the anti-polio campaigns of the 1950s and 1960s.

"This should be very reassuring. An independent regulatory authority in another country has found this vaccine to be safe and effective for use," U.S. Health Secretary Alex Azar told Fox Business Network on Wednesday.

U.S. COVID-19 hospitalizations hit a record for a fourth consecutive day on Tuesday, approaching 100,000, according to a Reuters tally. At the same time, exhausted healthcare professionals are short-staffed, with many of their colleagues falling sick.

Another 2,624 U.S. deaths were reported on Tuesday, the fifth-highest daily total on record, raising the cumulative death toll above 270,000 since the pandemic began. At least four states - Illinois, Kansas, Minnesota and Oklahoma - reported a record increase in deaths on Wednesday.

Although China and Russia also have moved ahead with inoculation campaigns with their own vaccines, Britain's medical standards more closely align with those of the United States.

"It's got major significance being that it's the first Western country to approve the vaccine for a roll-out and start administering it to the public," said Kirsten Hokeness, an immunology and virology expert and chair of Science and Technology at Bryant University in Smithfield, Rhode Island.

"It's going to put a little pressure on us to rapidly evaluate the data," Hokeness said.

A U.S. Food and Drug Administration (FDA) panel of outside advisers will meet on Dec. 10 to discuss whether to recommend emergency use authorization of the Pfizer vaccine. Moderna's vaccine, which employs similar technology as Pfizer's and was also nearly 95% effective in preventing illness in a pivotal clinical trial, is expected to be reviewed a week later.

Of particular interest is how Britain manages the Pfizer vaccine's requirement to be stored at minus-70 degrees Celsius (-94 Fahrenheit). Moderna's can be kept at more normal refrigerator temperatures.

But the British experience is unlikely to factor into U.S. regulatory approval, which instead will focus on the clinical trial data.


While some U.S. health officials described a timeline that assumed FDA authorization would come within days of the Dec. 10 meeting, others have said it could take weeks.

"Surely we want a vaccine available as soon as it is deemed safe. We want to make sure that we can provide accurate information to the public," said Dr. Lisa Costello, a professor of pediatrics at the West Virginia University School of Medicine who is helping advise West Virginia's state government on vaccine distribution.

Virginia Governor Ralph Northam expressed confidence in the safety of the vaccines at a news conference on Wednesday.

"As a doctor, I am confident that all protocols have been followed and no corners have been cut," he said.

Pfizer, Moderna and AstraZeneca Plc have already started manufacturing their vaccines and say distribution could begin almost immediately after approval. AstraZeneca, however, may have to conduct an additional trial to gain U.S. approval after a dosing error led to better results in recently released data than for its planned regimen.

Moderna, which has millions of doses ready to be shipped, expects its vaccine could be approved for emergency use within 24 to 72 hours after the FDA advisory committee meeting on Dec. 17, Chief Executive Stéphane Bancel said on Wednesday.

Beyond regulatory hurdles, vaccinations face opposition from significant numbers of Americans who reject medical science and fear vaccines as harmful.

Similarly, many Americans still refuse to follow basic public health guidance on wearing masks and avoiding crowds, even as the pandemic killed 10,000 people and infected 1.1 million last week alone in the United States.

"A vaccine will be the single most important tool we have to fight COVID, but it's not going to turn things around overnight," Dr. Tom Frieden, former director of the U.S. Centers for Disease Control and Prevention, wrote on Twitter.

"We must do much better at knocking the virus down with nuanced, well-timed closures and measures such as rapid testing, isolation, and contact tracing."

In hopes of increasing compliance, the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday added new guidelines for shorter quarantines after coronavirus exposure.

The health agency said seven days with a negative COVID-19 test and 10 days without a test would work for individuals showing no symptoms after exposure to the virus. But it still recommends a 14-day quarantine period as the best way to reduce its spread.

(Reporting by Daniel Trotta, Nathan Layne, Doina Chiacu, Maria Caspani, Caroline Humer, Lisa Shumaker, Peter Szekely, Susan Heavey, Mrinalika Roy and Trisha Roy; Editing by Bill Berkrot and Rosalba O'Brien)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.44% 7592 Delayed Quote.3.66%
MODERNA, INC. -0.05% 129.65 Delayed Quote.24.10%
All news about ASTRAZENECA PLC
02:23pASTRAZENECA : Brazil's health agency approves the use of two vaccines
02:10pASTRAZENECA : Brazil Starts Its Covid-19 Vaccine Rollout -- 3rd Update
01:52pASTRAZENECA : Brazil Authorizes Use of Two Covid-19 Vaccines -- Update
01:39pBrazil Authorizes Use of Two Covid-19 Vaccines
01:28pASTRAZENECA : Brazil clears emergency use of Sinovac, AstraZeneca vaccines, shot..
10:07aASTRAZENECA : Brazil regulator to decide on emergency use of Sinovac, AstraZenec..
03:55aSwiss to get Moderna vaccine in tranches until mid-year - Blick
01:32aTHE LATEST : Pakistan approves Oxford-AstraZeneca vaccine
01/16THE LATEST : Biden elevates science adviser to Cabinet level
01/16ASTRAZENECA : India starts world's largest COVID-19 vaccination drive
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,0x
Yield 2020 2,73%
Capitalization 135 B 135 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,14 $
Spread / Highest target 51,3%
Spread / Average Target 22,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993